clinical trial · NCT05297448
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Bausch Health Americas, Inc.·phase3·active not recruiting·n = 466
Hepatic EncephalopathyRifaximin SSDPlacebo
brief summary
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
started
Aug 3, 2022
primary completion
Jan 1, 2026
completion
Jan 1, 2026
last updated
Sep 10, 2025
official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol